Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the safety, tolerability, and PK of single and multiple ascending doses of VX-840 in healthy participants.


Clinical Trial Description

This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05324410
Study type Interventional
Source Vertex Pharmaceuticals Incorporated
Contact
Status Completed
Phase Phase 1
Start date April 7, 2022
Completion date November 7, 2022